XRHealth and HTC Introduce “Flow Health” and “Focus 3 Health” at HIMSS 2022

Both Solutions Provide Portable Virtual Reality Healthcare Solutions for Hospitals, Rehabilitation Centers, and Patients to Use in the Comfort of their Home

XRHealth, the gateway to the healthcare metaverse,  and HTC VIVE, the global leader in premium virtual reality (VR),  announced today “Focus 3 Health” and “Flow Health” powered by XRHealth.

The two separate products using HTC VIVE Focus 3 and HTC VIVE Flow are preloaded with the XRHealth virtual reality treatment rooms and other VR health applications, so that hospitals, rehabilitation centers and individual patients can benefit from remote VR telehealth, no matter where they are.

Individual patients can purchase “Flow Health” for $599. The bundle includes the VIVE Flow immersive glasses, preloaded with XRHealth FDA registered medical applications, and includes a screening video call with an XRHealth clinician. Patients can then sign up for VR Telehealth treatment with an XRHealth clinician, covered by their health plan or pay out of pocket for $69-$119 per week, according to the tier they choose.

Hospitals and rehabilitation centers can purchase the “Focus 3 Health” solution for a $1300 one-time fee, which includes the VIVE Focus 3 headset and the preinstalled XRHealth medical platform. The XRHealth medical platform applications are a subscription service of $1000/month. The devices will be sold under the guidelines and regulations of durable medical equipment and will be FSA/HSA eligible.

“XRHealth, together with HTC, are excited to offer the public VR products specifically designed for the healthcare market,” says Eran Orr, Chief Executive Officer of XRHealth. “We believe in creating healthcare solutions that are limitless and provide continuous access and healthcare opportunities to patients around the globe.”

XRHealth’s healthcare VR applications are FDA and CE registered and transport patients to a virtual clinic, where symptoms of stress, anxiety, depression, ADHD, autism, multiple sclerosis, Parkinson’s Disease, and physical and neurological injuries are treated.  When the patient is in the treatment room, comprehensive data can be measured providing the clinician with valuable insights on treatment progress and outcome.

“At HTC, we believe in the power of VR to change lives,” said Amir Khorram, VP of Enterprise Sales, at HTC VIVE. “We are honored to partner with XRHealth on Flow Health and Focus 3 Health – two innovative solutions centered around the power of the VIVE Focus 3 and the lightweight portability of the VIVE Flow, to offer patients and clinicians immersive remote VR telehealth treatments.”

Both products will be available in June. Customers can preorder here, beginning May 1, 2022.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy